France · Delayed Price · Currency is EUR Neurones Statistics
Total Valuation
Neurones has a market cap or net worth of EUR 854.75 million. The enterprise value is 651.77 million.
| Market Cap | 854.75M |
| Enterprise Value | 651.77M |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Neurones has 23.84 million shares outstanding. The number of shares has decreased by -0.28% in one year.
| Current Share Class | 23.84M |
| Shares Outstanding | 23.84M |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | -0.97% |
| Owned by Insiders (%) | 4.50% |
| Owned by Institutions (%) | 8.29% |
| Float | 11.60M |
Valuation Ratios
The trailing PE ratio is 15.72 and the forward PE ratio is 15.39.
| PE Ratio | 15.72 |
| Forward PE | 15.39 |
| PS Ratio | 0.96 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 2.73 |
| P/FCF Ratio | 10.79 |
| P/OCF Ratio | 9.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.46, with an EV/FCF ratio of 8.23.
| EV / Earnings | 11.80 |
| EV / Sales | 0.73 |
| EV / EBITDA | 6.46 |
| EV / EBIT | 7.96 |
| EV / FCF | 8.23 |
Financial Position
The company has a current ratio of 2.23, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.23 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.53 |
| Interest Coverage | 61.81 |
Financial Efficiency
Return on equity (ROE) is 15.32% and return on invested capital (ROIC) is 34.20%.
| Return on Equity (ROE) | 15.32% |
| Return on Assets (ROA) | 7.07% |
| Return on Invested Capital (ROIC) | 34.20% |
| Return on Capital Employed (ROCE) | 17.52% |
| Weighted Average Cost of Capital (WACC) | 6.38% |
| Revenue Per Employee | 121,130 |
| Profits Per Employee | 7,538 |
| Employee Count | 7,329 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 40,667.36 |
Taxes
In the past 12 months, Neurones has paid 25.34 million in taxes.
| Income Tax | 25.34M |
| Effective Tax Rate | 27.67% |
Stock Price Statistics
The stock price has decreased by -11.11% in the last 52 weeks. The beta is 0.42, so Neurones's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -11.11% |
| 50-Day Moving Average | 37.20 |
| 200-Day Moving Average | 37.20 |
| Relative Strength Index (RSI) | 40.26 |
| Average Volume (20 Days) | 5,109 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neurones had revenue of EUR 887.76 million and earned 55.24 million in profits. Earnings per share was 2.28.
| Revenue | 887.76M |
| Gross Profit | 440.42M |
| Operating Income | 81.90M |
| Pretax Income | 91.58M |
| Net Income | 55.24M |
| EBITDA | 93.51M |
| EBIT | 81.90M |
| Earnings Per Share (EPS) | 2.28 |
Balance Sheet
The company has 301.88 million in cash and 41.72 million in debt, with a net cash position of 260.16 million or 10.91 per share.
| Cash & Cash Equivalents | 301.88M |
| Total Debt | 41.72M |
| Net Cash | 260.16M |
| Net Cash Per Share | 10.91 |
| Equity (Book Value) | 433.34M |
| Book Value Per Share | 15.78 |
| Working Capital | 323.55M |
Cash Flow
In the last 12 months, operating cash flow was 91.36 million and capital expenditures -12.18 million, giving a free cash flow of 79.19 million.
| Operating Cash Flow | 91.36M |
| Capital Expenditures | -12.18M |
| Depreciation & Amortization | 11.62M |
| Net Borrowing | -9.20M |
| Free Cash Flow | 79.19M |
| FCF Per Share | 3.32 |
Margins
Gross margin is 49.61%, with operating and profit margins of 9.22% and 6.22%.
| Gross Margin | 49.61% |
| Operating Margin | 9.22% |
| Pretax Margin | 10.32% |
| Profit Margin | 6.22% |
| EBITDA Margin | 10.53% |
| EBIT Margin | 9.22% |
| FCF Margin | 8.92% |
Dividends & Yields
This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 3.98%.
| Dividend Per Share | 1.40 |
| Dividend Yield | 3.98% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 60.45% |
| FCF Payout Ratio | 42.15% |
| Buyback Yield | 0.28% |
| Shareholder Yield | 4.19% |
| Earnings Yield | 6.46% |
| FCF Yield | 9.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neurones has an Altman Z-Score of 4.11 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.11 |
| Piotroski F-Score | 7 |